Advertisement

Screening with X-rays

In the October Nature Biotechnology, Nienaber et al. demonstrate that drug or inhibitor leads can be identified by high throughput X-ray crystallography (Nat. Biotech. 2000, 18:1105-1108). Pre-formed protein crystals are soaked in solvents containing mixtures of 100 compounds before the crystals are examined by X-ray crystallography. Nienaber et al. look for changes in the electron-density map caused by ligand binding. The compounds in each mixture are chosen to be diverse in shape so that they

By | October 10, 2000

In the October Nature Biotechnology, Nienaber et al. demonstrate that drug or inhibitor leads can be identified by high throughput X-ray crystallography (Nat. Biotech. 2000, 18:1105-1108). Pre-formed protein crystals are soaked in solvents containing mixtures of 100 compounds before the crystals are examined by X-ray crystallography. Nienaber et al. look for changes in the electron-density map caused by ligand binding. The compounds in each mixture are chosen to be diverse in shape so that they can be differentiated readily, and the technique allows the site and orientation of binding to be identified. Nienaber et al. use this method to screen thousands of compounds per day in a successful search for a high affinity inhibitor of the anti-cancer target urokinase.

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
NuAire Inc.
NuAire Inc.
Advertisement
The Scientist
The Scientist